why choose us

First received: January 23, 2023

Clinical Trial: Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Diffuse Glioma

Study Type: INTERVENTIONAL


Official Title: Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501

Brief Summary: This early phase I trial studies brain tumor (glioma) metabolism in response to eflornithine (DFMO) and polyamine transport inhibitor AMXT-1501 dicaprate (AMXT 1501) in patients with diffused or high grade glioma.Brain tumors use and produce certain molecules to survive and grow.DFMO is an irreversible inhibitor of ornithine decarboxylase, the enzyme catalyzing polyamine synthesis.AMXT 1501 is a polyamine transport inhibitor which prevents uptake of polyamines from the extracellular environment.This trial is being…

Read more